Coinfection
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
Coverage of the 2017 Harm Reduction International Conference
- Details
- Category: HIV Treatment
- Published on Wednesday, 31 May 2017 00:00
- Written by HIVandHepatitis.com
HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.
5/31/17
CROI 2016: HIV/HBV Coinfection Linked to Worse Immune Recovery and Death
- Details
- Category: HIV/HBV Coinfection
- Published on Wednesday, 06 April 2016 00:00
- Written by Liz Highleyman
HIV-positive people with hepatitis B virus (HBV) coinfection had impaired CD4 cell recovery after starting antiretroviral (ART) and a higher risk of death than those without hepatitis B, but use of ART regimens containing tenofovir significantly reduced mortality, according to a study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston.
Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Sunday, 16 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.
Full coverage listing by topic
4/16/17
Coverage of the 2016 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Friday, 26 February 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 Conference on Retroviruses and Opportunistic infections (CROI 2016), February 22-25, 2016, in Boston.
HIVandHepatitis.com coverage by topic
2/26/16
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Sunday, 20 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/20/16
Coverage of the 2015 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Monday, 23 November 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.
Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.
11/23/15
AIDS 2016: Ongoing Hepatitis B Virus Replication Raises Mortality for People with HIV
- Details
- Category: HIV/HBV Coinfection
- Published on Thursday, 04 August 2016 00:00
- Written by Liz Highleyman
People with HIV and hepatitis B virus (HBV) coinfection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for prompt treatment, according to an analysis from the Temprano trial presented at an HIV and viral hepatitis coinfection session at the 21st International AIDS Conference (AIDS 2016) last month in Durban.
Antiretroviral Treatment for HIV Appears to Protect Gay Men Against Hepatitis B
- Details
- Category: HIV/HBV Coinfection
- Published on Monday, 19 October 2015 00:00
- Written by Liz Highleyman
HIV-positive gay and bisexual men who use effective combination antiretroviral therapy (ART) were 80% less likely to become infected with hepatitis B virus (HBV) in a large observational study reported in the October 13 Annals of Internal Medicine. The authors emphasize, however, that ART is not a substitute for hepatitis B vaccination.